Jefferies Group LLC Collegium Pharmaceutical, Inc Call Options Transaction History

Jefferies Group LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Sep 21, 2023	BUY	$15.46 - $20.1 $448,340 - $582,900	29,000 Added 232.0%	41,500 $664,000
Q3 2022 Nov 14, 2022	BUY	$15.46 - $20.1 $641,590 - $834,150	41,500 New	41,500 $665,000
Q2 2021 Aug 16, 2021	SELL	$21.74 - $25.28 $271,750 - $316,000	-12,500 Closed	0 $0
Q4 2020 Sep 21, 2023	SELL	$17.83 - $22.29 $517,069 - $646,410	-29,000 Reduced 69.88%	12,500 $250,000
Q4 2020 Feb 16, 2021	BUY	$17.83 - $22.29 $222,874 - $278,625	12,500 New	12,500 $250,000
Q3 2019 Nov 13, 2019	SELL	$10.16 - $13.28 $862,584 - $1.13 Million	-84,900 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.62 - $16.59 $901,637 - $1.41 Million	84,900 New	84,900 $1.12 Million

255

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $977M
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.